Autoimmune Disease Diagnostics Market By Test Type (Autoantibody Tests, Antinuclear Antibody (ANA) Tests, Complete Blood Count (CBC) Tests, C-Reactive Protein (CRP) Tests, Erythrocyte Sedimentation Rate (ESR) Tests, Urinalysis, Imaging Tests), By Disease Type (Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Type 1 Diabetes, Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD), Psoriasis, Hashimoto’s Thyroiditis), By End-User (Hospitals, Diagnostic Laboratories, Research Laboratories, Academic Institutes), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Autoimmune Disease Diagnostics Market was valued at USD 4.9 billion in 2023 and will surpass USD 7.7 billion by 2030; growing at a CAGR of 6.8% during 2024 - 2030.

The autoimmune disease diagnostics market is witnessing robust growth due to increasing prevalence of autoimmune disorders, advancements in diagnostic technologies, and heightened awareness about early disease detection. Autoimmune diseases, such as rheumatoid arthritis, lupus, and type 1 diabetes, affect millions globally, driving demand for accurate and efficient diagnostic tools. The market is segmented based on test types, disease types, and end-users, each offering unique opportunities for growth and innovation.

Autoantibody Tests Segment Is Largest Owing to Its Diagnostic Precision

Autoantibody tests hold the largest share in the autoimmune disease diagnostics market, primarily due to their high sensitivity and specificity in identifying autoimmune disorders. These tests detect antibodies produced by the immune system against the body’s tissues, enabling early and accurate diagnosis of diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

The increasing prevalence of autoimmune diseases, coupled with advancements in biomarker research, has bolstered the adoption of autoantibody tests. Moreover, these tests are widely used in clinical and laboratory settings for their reliability and cost-effectiveness, making them the preferred choice among healthcare professionals. As technological innovations continue, the segment is expected to maintain its leadership position.

Rheumatoid Arthritis Segment Leads Due to High Global Incidence

Among disease types, the rheumatoid arthritis (RA) segment dominates the market due to the high prevalence of the condition and the availability of multiple diagnostic modalities. RA affects millions of individuals worldwide and is characterized by chronic inflammation and joint damage, necessitating precise diagnostic tools.

Innovations in diagnostic assays, including biomarkers and imaging technologies, have significantly enhanced the accuracy of RA diagnosis. Increasing awareness among patients and healthcare providers has also contributed to early disease identification, enabling timely intervention and improved patient outcomes. With ongoing research into RA pathogenesis, the segment is poised for sustained growth.

Diagnostic Laboratories Segment Is Fastest Growing Owing to Technological Advancements

The diagnostic laboratories segment is the fastest-growing end-user category in the autoimmune disease diagnostics market. Laboratories are increasingly adopting cutting-edge technologies, such as automated diagnostic platforms and advanced imaging systems, to improve diagnostic accuracy and efficiency.

The central role of diagnostic laboratories in the healthcare ecosystem, combined with growing investments in laboratory infrastructure, has fueled this growth. Furthermore, partnerships between diagnostic labs and biotechnology companies to develop novel assays and tests have further enhanced the segment’s expansion prospects.

North America Leads the Market Owing to Advanced Healthcare Infrastructure

North America holds the largest market share in the autoimmune disease diagnostics market, driven by its advanced healthcare infrastructure, high disease awareness, and significant investments in diagnostic research. The region boasts a strong network of hospitals, diagnostic laboratories, and research institutions that facilitate the adoption of innovative diagnostic technologies.

Government initiatives to improve autoimmune disease management and an increasing focus on personalized medicine are additional growth drivers. The presence of leading diagnostic companies further strengthens the region’s position as a market leader.

Leading Companies and Competitive Landscape

The autoimmune disease diagnostics market is highly competitive, with prominent players such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers leading the way. These companies are investing heavily in research and development to introduce innovative diagnostic solutions. Collaborations, acquisitions, and product launches are common strategies to strengthen market presence.

Emerging players are also gaining traction by focusing on niche diagnostic areas and leveraging advanced technologies like AI and machine learning. As the market evolves, the competitive landscape is expected to intensify, fostering innovation and improving diagnostic outcomes for patients globally.

Recent Developments:

• Abbott introduced a next-generation autoantibody diagnostic platform, improving sensitivity for early autoimmune disease detection.
• Roche expanded its autoimmune diagnostics portfolio by acquiring an innovative serology testing company.
• Siemens received FDA clearance for a novel CRP diagnostic test for rapid autoimmune disease assessment.
• Bio-Rad partnered with global diagnostic laboratories to expand access to advanced autoimmune testing solutions.
• EUROIMMUN announced the establishment of new facilities in Asia-Pacific to enhance autoimmune diagnostic services.

List of Leading Companies:

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Danaher Corporation
• Beckman Coulter, Inc.
• Quest Diagnostics
• EUROIMMUN (A PerkinElmer Company)
• Inova Diagnostics
• Grifols, S.A.
• Myriad Genetics
• Trinity Biotech
• Hologic, Inc.
• Ortho Clinical Diagnostics

Report Scope: